Literature DB >> 8877758

HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C.

T Aikawa1, M Kojima, H Onishi, R Tamura, S Fukuda, T Suzuki, F Tsuda, H Okamoto, Y Miyakawa, M Mayumi.   

Abstract

Some HLA class II alleles and haplotypes were examined by restriction fragment length polymorphism of corresponding DNA fragments amplified by the polymerase chain reaction in 117 patients with chronic hepatitis C in Japan. The prevalence rates were compared between patients and 1216 controls and in 67 patients with liver cirrhosis, of whom 20 had hepatocellular carcinoma and 50 patients with chronic hepatitis who did not have cirrhosis or hepatocellular carcinoma. Notably, DRB1*0405 (49% [95% confidence range 38-60%] vs. 26% [16-40%]; P < 0.05, relative risk [rr] = 2.8) and DQB1*0401 (43% [33-54%] vs. 22% [13-34%]; P < 0.05, rr = 2.1) were detected more frequently in patients with cirrhosis than in those without cirrhosis. By contrast, DRB1*0901 (11% [6-19%] vs. 28% [18-40%]; P < 0.05; rr = 0.3) and DQB1*0303 (11% [6-19%] vs. 36% [25-49%]; P < 0.01; rr = 0.2) were detected less frequently in patients with cirrhosis than those without cirrhosis. Accordingly, the DRB1*0405-DQB1*0401 haplotype was more common (43% [33-54%] vs. 22% [13-34%]; P < 0.05; rr = 2.7), while the DRB1*0901-DQB1*0303 haplotype was less common (9% [4-17%] vs. 28% [18-40%]; P < 0.05; rr = 0.3) in patients with cirrhosis than in those without cirrhosis. These results suggest that there would be HLA class II alleles and haplotypes which may be associated with an accelerated or slower progression of chronic hepatitis C towards cirrhosis and eventually to hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877758     DOI: 10.1002/(SICI)1096-9071(199608)49:4<274::AID-JMV3>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Lack of evidence for the Th2 predominance in patients with chronic hepatitis C.

Authors:  A Bergamini; F Bolacchi; G Cerasari; C Carvelli; E Faggioli; M Cepparulo; F Demin; I Uccella; B Bongiovanni; P Niutta; M Capozzi; M Lupi; E Piscitelli; G Rocchi; M Angelico
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

3.  Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.

Authors:  Leland J Yee; KyungAh Im; Abdus S Wahed; Teodorica Bugawan; Jia Li; Shannon L Rhodes; Henry Erlich; Hugo R Rosen; T Jake Liang; Huiying Yang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 4.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

5.  Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  BMC Gastroenterol       Date:  2010-12-21       Impact factor: 3.067

6.  Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome.

Authors:  Thi Phuong Lan Nguyen; Mihoko Kikuchi; Thi Que Huong Vu; Quang Ha Do; Thi Thuy Tran; Dinh Tham Vo; Manh Tuan Ha; Van Tuong Vo; Thi Phi Nga Cao; Van Dat Tran; Toshifumi Oyama; Kouichi Morita; Michio Yasunami; Kenji Hirayama
Journal:  PLoS Negl Trop Dis       Date:  2008-10-01

7.  Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients.

Authors:  Serkan Ocal; Haldun Selcuk; Murat Korkmaz; Reskan Altun; Abdullah E Yildirim; Enver Akbas
Journal:  Saudi J Gastroenterol       Date:  2014 May-Jun       Impact factor: 2.485

8.  Maneuvering for advantage: the genetics of mouse susceptibility to virus infection.

Authors:  Seung-Hwan Lee; Ken Dimock; Douglas A Gray; Nicole Beauchemin; Kathryn V Holmes; Majid Belouchi; John Realson; Silvia M Vidal
Journal:  Trends Genet       Date:  2003-08       Impact factor: 11.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.